References
- Shields RK, Clancy CJ, Gillis LM et al. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS ONE 7(12), e52349 (2012).
- Aydemir H, Akduman D, Piskin N et al. Colistin vs the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol. Infect. 141(6), 1214–1222 (2013).
- Song JY, Lee J, Heo YJ et al. Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Int. J. Antimicrob. Agents 32(3), 281–284 (2008).
- Petrosillo N, Chinello P, Proietti MF et al. Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. Clin. Microbiol. Infect. 11(8), 682–683 (2005).
- Bassetti M, Repetto E, Righi E et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J. Antimicrob. Chemother. 61(2), 417–420 (2008).
- Durante-Mangoni E, Signoriello G, Andini R et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant acinetobacter baumannii: a multicenter, randomized clinical trial. Clin. Infect. Dis. (2013) ( Epub ahead of print).
- Giamarellos-Bourboulis EJ, Xirouchaki E, Giamarellou, H. Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn. Microbiol. Infect. Dis. 40(3), 117–1120 (2001).
- Garonzik SM, Li J, Thamlikitkul, V et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother. 55(7), 3284–3294 (2011).
- Pogue JM, Lee J, Marchaim D et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin. Infect. Dis. 53(9), 879–884 (2011).
- Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob. Agents Chemother. 54(10), 4503–4505 (2010).
- Hartzell JD, Neff R, Ake J et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin. Infect. Dis. 48(12), 1724–1728 (2009).
- Sirijatuphat R, Koomanachai, P, Thamlikitkul V. Randomized Controlled Trial of Colistin versus Colistin plus Fosfomycin for Infections Caused by Carbapenem-Resistant Acinetobacter baumannii. The 9th International Symposium on Antimicrobial Agents and Resistance (ISAAR 2013). Kuala Lumpur, Malaysia, 13–15 March (2013).